To provide a rapid and systematic review of the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine and galantamine in the symptomatic treatment of people suffering from Alzheimer's disease (AD).
Data extraction
The data were extracted from the included studies by one reviewer and checked by a second. Any discrepancies were resolved by discussion between the reviewers.
The data extracted from the systematic reviews included: study authorship; publication year; country; study design; research question; search strategy details; inclusion and exclusion criteria; interventions; patient characteristics; results, i.e. global, cognitive, and functional and quality of life outcome measures, and information on adverse effects; methodology used; general comments; and the overall CRD quality score and the criteria assessed.
The data extracted from the RCTs included: study authorship; publication year; study design; intervention details including drug, dose and duration, and details of cointerventions; the total number of patients in each arm; characteristics of the target population; exclusion criteria; details of the participants; study setting; results, i.e global, cognitive, and functional and quality of life outcome measures, and information on adverse effects; methodology used; general comments; and the overall Jadad quality score and the criteria assessed.
The extracted data were presented in tabular format: a summary of the data was tabulated in the main body of the report, while more comprehensive tables of data were provided in the appendices.
Methods of synthesis
How were the studies combined?
The studies were grouped according to the agent being investigated, i.e. studies which investigated donepezil, rivastigmine or galantamine were grouped with other studies assessing the same drug.
A narrative overview was presented. This commented on the quantity and quality of the research evidence base for the use of each drug in the treatment of AD, and on the clinical effectiveness (including adverse effects) of the drug.
The authors did not pool the studies in a meta-analysis.
How were differences between studies investigated?
The authors do not report a formal assessment of the heterogeneity of the studies. However, they did discuss some elements that may have led to differences between the studies. This included the quality of the studies, variability of the inclusion and exclusion criteria, variations in the doses of individual drugs, and differences in the follow-up procedures.
Results of the review
A total of 26 studies were included. Twelve studies investigated donepezil: 3 systematic reviews, 5 RCTs (n=1,980) and 4 studies submitted by the drug manufacturers as 'Commercial in Confidence' (CIC; n=1,133). Ten studies investigated rivastigmine: 3 systematic reviews, 5 RCTs (n=1,990) and 2 studies submitted as CIC (n=1,380). Six studies investigated galantamine: no systematic reviews, 3 RCTs (n=1,614) and 3 studies submitted as CIC (n=1,324).
Donepezil.
The information found suggested that donepezil is beneficial for the treatment of patients with mild to moderate AD when assessed using both global and cognitive outcome measures. However, the effects were small and may not translate into a clinical benefit. The side-effects included nausea, vomiting and diarrhoea but these were usually mild and transient. The generalisability of these findings may be limited to those patients with mild to moderate AD, and to those with limited co-morbidity or concomitant interventions.
Rivastigmine.
The information found suggested that rivastigmine is beneficial for the treatment of patients with AD when assessed using both global and cognitive outcome measures. Statistically-significant cogitative and functional outcomes were not reported in all studies. Improvements on these scales may not lead to clinical improvement. The adverse events included nausea, vomiting diarrhoea, headaches, dizziness, abdominal pain, fatigue, malaise, anxiety and agitation. The
